Pit Viper Snakebite Management Pathway

BACKGROUND

- Pit Viper snake envenomation is a dynamic clinical process.
- Pit Viper snakes include copperheads, rattlesnakes, and water moccasins (cottonmouths).
- Clinical toxicity is manifested by local toxicity, systemic toxicity, and a multicomponent coagulopathy. The development and progression of these toxicities depends on the type of snake, the number of bites, and/or the potency of the venom.
- Serial examinations and laboratory studies are necessary to detect ongoing, recurrent, or delayed-onset venom effects.
- A photo of the snake may be helpful in its identification and in anticipating the potential severity of toxicity, observation times, and need for serial laboratory monitoring. Do NOT bring snake into the healthcare facility.
- Copperhead snakebites many times do not result in as severe envenomation as those from rattlesnakes and water moccasins (cottonmouths). Shorter observation times and less frequent laboratory monitoring may be acceptable for known envenomations from these snakes.
- Anaphylactic and anaphylactoid reactions to the snake venom itself are uncommon manifestations of snakebites but can occur and range in severity from urticarial rash to multisystem organ failure and angioedema causing airway loss.
- This clinical pathway is NOT for coral snake envenomations.

ANTIVENOM

Types:

- There are 2 antivenoms approved for pit viper envenomation in the United States
  - CroFab® Crotalidae polyvalent immune Fab [ovine] – on ACH Formulary
  - Anavip® Crotalidae immune F(ab')2 [equine]
- ACH only has CroFab® on formulary but patients may be transferred having received Anavip®
- These antivenoms are dosed differently initially: initial dose of Anavip® is 10 vials for all patients of all ages.

Infusion of Antivenom:

- Initial dose: start antivenom infusion at a slow initial rate (e.g., 25mL/hr for 10 minutes) followed by an increased infusion rate (balance of dose administered over 50 minutes) if no acute hypersensitivity reaction is observed.
- First dose of antivenom should be administered in a clinical setting such as an emergency department or intensive care unit where the medications, equipment, and skilled personnel required to manage an airway emergency are immediately available.
- If there is no acute reaction to initial dosing, subsequent doses of antivenom can be administered in a less monitored setting.

Adverse effects of antivenom:

- CroFab® antivenom is contraindicated in patients allergic to papain or papaya.
- Symptoms of anaphylactoid reactions, such as pruritus, urticaria, or wheezing occur in approximately 6% of patients.
- Carefully monitor patients for signs and symptoms of an acute allergic reaction (e.g., urticaria, pruritus, erythema, angioedema, bronchospasm with wheezing or cough, stridor, laryngeal edema, hypotension, tachycardia).
- Most cases are mild and do not preclude continued administration of antivenom.
- Infusion reactions such as fever, back pain, wheezing, and nausea may be related to the rate of infusion and can be controlled by decreasing the rate of infusion.
- If patient develops allergic or other reaction (hives, pruritus), stop infusion and administer antihistamines and restart the infusion at a lower rate.
- Severe acute hypersensitivity reactions or true immune-mediated anaphylaxis demonstrated by airway compromise or hypotension are rare but can occur. Discontinue antivenom and institute appropriate emergency treatment (epinephrine, IV antihistamines, albuterol, steroids). See Anaphylaxis Clinical Pathway
- There are a few published reports of patients developing anaphylactic reactions to CroFab who were found to be sensitized to alpha-Gal or galactose-α-1,3-galactose and suggest that IgE to α-gal may have been relevant to that reaction. Alpha-Gal sensitization is caused by tick bites and alpha-gal syndrome/allergy may occur after people eat red meat. In the United States, IgE to alpha-Gal has a regional distribution that is most pronounced in southeastern states where mammalian meat allergy is common.
- The decision to resume or discontinue antivenom therapy involves a complex balancing of risk and benefit and should be in consultation with Clinical Pharmacology/Toxicology attending and other specialists as needed.
Pit Viper Snakebite Management Pathway

**Inclusion Criteria:**
Snakebite by Pit Viper Snake Species:
- Rattlesnakes
- Copperheads
- Water Moccasins (cottonmouths)

**Treatments to AVOID in Pit Viper Snakebite**
- Cutting and/or suctioning of the wound
- Ice
- NSAIDs
- Prophylactic antibiotics
- Prophylactic fasciotomy
- Routine use of blood products
- Shock therapy (electricity)
- Steroids (except for allergic phenomena)
- Tourniquets

**Assess Patient**
- Mark leading edge of swelling and tenderness every 30-60 minutes
- Immobilize and elevate extremity
- Treat pain (IV opioids preferred)
- Obtain initial lab studies (CBC, protime, fibrinogen)
- Update Tetanus
- Contact poison center (1-800-222-1222)

**Check for Signs of Envenomation**
- Swelling, tenderness, redness, edema, or blebs at the bite site, or
- Elevated protime, decreased fibrinogen or platelets, or
- Systemic signs, such as hypotension, bleeding beyond the puncture site, refractory vomiting, diarrhea, angioedema, neurotoxicity

**Check for Indications for CroFab® Antivenom**
- Swelling that is more than minimal and that is progressing, or
- Elevated protime; decreased fibrinogen or platelets, or
- Any systemic signs

**Administer CroFab® Antivenom**
- Establish IV access and give IV fluids
- Pediatric CroFab® antivenom dose = adult dose
- Mix 4-6 vials of crotalineline Fab antivenom (CroFab®) in 250mL NS and infuse IV over 1 hour
  - For patients in shock or with serious active bleeding
  - Increase initial dose of CroFab® antivenom to 8-12 vials
  - Call Clinical Pharmacology/Toxicology or APCR
- Initiate first dose of antivenom in ED or ICU
  - For suspected adverse reaction (see Background pg. 3): hold infusion, treat accordingly, and call Medical Toxicologist
  - Re-examine patient for treatment response within 1 hour of completion of antivenom infusion

**Determine if initial control of envenomation has been achieved:**
- Swelling and tenderness not progressing
- Protime, fibrinogen, and platelets normal or clearly improving
- Clinically stable (not hypotensive, etc)
- Neurotoxicity resolved or clearly improving

**Monitor Patient**
- Perform serial examinations
- Maintenance CroFab® antivenom therapy may be indicated
- See Maintenance CroFab® Antivenom Therapy
- Observe patient 16-36 hours after initial control for progression of any venom effect
  - Shorter observation times and less laboratory monitoring may be acceptable for known copperhead bites. Consult Clinical Pharmacology/Toxicology for recommendations.
  - Follow-up labs 6-12 hours after initial control and prior to discharge
  - If patient develops new or worsening signs of envenomation, administer additional CroFab® antivenom

**Determine if Patient Meets Discharge Criteria**
- No progression of any venom effect during the specified observation period
- No unfavorable laboratory trends in protime, fibrinogen, or platelets

**Notes:**
All treatment recommendations in this algorithm refer to CroFab®

This worksheet represents general advice from a panel of US snakebite experts convened in May, 2010. No algorithm can anticipate all clinical situations. Other valid approaches exist, and deviations from this worksheet based on individual patient needs, local resources, local treatment guidelines, and patient preferences are expected. This document is not intended to represent a standard of care. For more information, please see: biomedcentral.com
Pit Viper Snakebite Management Pathway

Maintenance CroFab® Antivenom Therapy

- Maintenance therapy is additional CroFab® antivenom given after initial control to prevent recurrence of limb swelling
  - Maintenance therapy is 2 vials of CroFab® antivenom Q6H x 3 (given 6, 12, and 18 hours after initial control)

- Maintenance therapy may not be indicated in certain situations, such as:
  - Minor envenomations
  - Some copperhead bites
  - Facilities where close observation by a medical toxicologist is available

- Contact Arkansas Poison and Drug Information (1-800-222-1222) or contact Clinical Pharmacology/Toxicology Service at ACH if patient is at ACH or ACNW
Pit Viper Snakebite Management Pathway

When to Consult Clinical Pharmacology/Toxicology or Medical Toxicologist either at ACH or APDIC

Direct consultation with a medical toxicologist is recommended in certain high-risk clinical situations.

- Life-threatening envenomations
  - Shock
  - Serious active bleeding
  - Facial or airway swelling

- Hard to control envenomation
  - Envenomation that requires more than 2 doses of antivenom for initial control

- Recurrence or delayed-onset of venom effects
  - Worsening swelling or abnormal labs (protime, fibrinogen, platelets, or hemoglobin) on follow-up visits

- Allergic reactions to antivenom

- If transfusion of blood products is considered

- Uncommon clinical situations
  - Bites to the head and neck
  - Rhabdomyolysis
  - Suspected compartment syndrome
  - Venom-induced hives and angioedema

- Complicated wound issues

_Call APDIC (1-800-222-1222) and request to speak with Medical Toxicologist on-call or consult with Clinical Pharmacology/Toxicology Service at ACH if patient is at ACH or ACNW._
Post-Discharge Planning

- Instruct patient to return for:
  - Worsening swelling that is not relieved by elevation
  - Abnormal bleeding (gums, easy bruising, melena, etc)

- Instruct patient where to seek care if symptoms of serum sickness (fever, rash, muscle/joint pains) develop

- Bleeding precautions (no contact sports, elective surgery or dental work, etc) for 2 weeks in patients with:
  - Rattlesnake envenomation
  - Abnormal protime, fibrinogen, or platelet count at any time

- Follow-up visits:
  - Antivenom not given:
    - PRN only
  - Antivenom given:
    - Copperhead victims: PRN only
    - Other snakes including unknown species with extensive local reaction, abnormal coagulation studies, and/or any hand envenomation: Follow-up with physical exam, labs (CBC, protime, fibrinogen) twice (2-3 days and 5-7 days), then PRN
Metrics

1. Length of stay
2. Total vials of antivenom – CroFab + Anavip from OSH
3. Fibrinogen ordered: Yes or No
4. Development of coagulopathy: PT > 15 or Fibrinogen < 170 mg/dL
5. Orderder set utilization
Contributing Members

Erica Liebelt, MD – Clinical Pharmacology/Toxicology and Pediatric Emergency Medicine
Hank Farrar, MD – Clinical Pharmacology/Toxicology
Patrick Ayers, MD – Pediatric Emergency Medicine Fellow
Abdallah Dalabih, MD – Clinical Effectiveness & Outcomes
Emily Rader, RN – Clinical Effectiveness & Outcomes
REFERENCES


